stockrowIonis Pharmaceuticals, Inc.
IONS Healthcare Biotechnology
Ionis Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $943.7 million, up 33.8% from fiscal 2024.
- Revenue
- −40.7%
- EPS
- −188.5%
- Free cash flow
- +299.3%
- Total debt
- +116.0%
Quarter to June 2026, against a year earlier
Follow IONS
Alert me
Ionis Pharmaceuticals, Inc. (IONS) Operating cash flow
Ionis Pharmaceuticals, Inc.'s operating cash flow for fiscal 2025 was −$268.6M, compared with −$500.9M in fiscal 2024. Over the twelve months to 30 June 2026 it was −$496.4M. Over the past ten years it has ranged from −$500.9M (fiscal 2024) to $602.9M (fiscal 2018); the current reading is higher than 36% of that period. Ionis Pharmaceuticals, Inc. ranks 596th of 603 Biotechnology companies by operating cash flow.
Operating cash flow, annual
Embed this chart
Annual newest first
| Period | Operating cash flow | Change |
|---|---|---|
| FY2025 | −$268.6M | — |
| FY2024 | −$500.9M | — |
| FY2023 | −$307.5M | — |
| FY2022 | −$274.4M | — |
| FY2021 | $30.8M | (14.19%) |
| FY2020 | $35.9M | (89.62%) |
| FY2019 | $345.6M | (42.67%) |
| FY2018 | $602.9M | 246.20% |
| FY2017 | $174.1M | — |
| FY2016 | −$112.1M | — |
Quarterly newest first
| Period | Operating cash flow | Change |
|---|---|---|
| Jun 2026 | $565.5M | — |
| Mar 2026 | −$792.8M | — |
| Dec 2025 | −$137.7M | — |
| Sep 2025 | −$131.4M | — |
| 42 more quarters | Free account |
Against its own ten years
Operating cash flow against peers
| Company | Operating cash flow |
|---|---|
| LGND Ligand Pharmaceuticals Incorporated compare | $91.0M |
| BLTE Belite Bio, Inc. Sponsored ADR compare | −$66.2M |
| AXSM Axsome Therapeutics, Inc. compare | −$81.8M |
| ORKA Oruka Therapeutics, Inc. compare | −$100.9M |
| KOD Kodiak Sciences Inc. compare | −$158.5M |
| CGON CG Oncology, Inc. compare | −$178.5M |
| MIRM Mirum Pharmaceuticals, Inc. compare | −$271.3M |
| IMVT Immunovant, Inc. compare | −$414.3M |
| IONS Ionis Pharmaceuticals, Inc. | −$496.4M |
What Operating cash flow is
Operating Cash Flow shows how much cash a company’s day-to-day business actually brings in, after paying suppliers, staff and taxes.
Reported line item
More on IONS
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement